$CARM
Carisma Therapeutics Inc

2014 Q2 Form 10-Q Financial Statement

#000119312514201170 Filed on May 15, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $761.0K $568.0K $0.00
YoY Change 276.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.050M $1.940M $940.0K
YoY Change 132.95% 106.38%
% of Gross Profit
Research & Development $6.754M $5.819M $4.496M
YoY Change 149.78% 29.43%
% of Gross Profit
Depreciation & Amortization $110.0K $100.0K $120.0K
YoY Change 0.0% -16.67%
% of Gross Profit
Operating Expenses $8.806M $7.757M $5.435M
YoY Change 145.63% 42.72%
Operating Profit -$8.045M -$7.189M -$5.435M
YoY Change 137.81% 32.27%
Interest Expense -$79.00K -$84.00K -$79.00K
YoY Change -42.34% 6.33%
% of Operating Profit
Other Income/Expense, Net -$76.00K -$33.00K -$77.00K
YoY Change -69.72% -57.14%
Pretax Income -$8.120M -$7.220M -$5.510M
YoY Change 123.69% 31.03%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.121M -$7.222M -$5.512M
YoY Change 123.47% 31.02%
Net Earnings / Revenue -1067.15% -1271.48%
Basic Earnings Per Share
Diluted Earnings Per Share -$505.6K -$749.0K -$4.408M
COMMON SHARES
Basic Shares Outstanding 16.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.00M $54.00M
YoY Change 533.8%
Cash & Equivalents $45.03M $53.96M $5.438M
Short-Term Investments
Other Short-Term Assets $1.000M $400.0K
YoY Change 66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.03M $54.41M
YoY Change 497.83%
LONG-TERM ASSETS
Property, Plant & Equipment $682.0K $708.0K
YoY Change -31.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K $18.00K
YoY Change
Total Long-Term Assets $791.0K $820.0K
YoY Change -20.9%
TOTAL ASSETS
Total Short-Term Assets $46.03M $54.41M
Total Long-Term Assets $791.0K $820.0K
Total Assets $46.82M $55.23M
YoY Change 438.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.602M $3.070M
YoY Change 271.71%
Accrued Expenses $1.140M $457.0K
YoY Change 280.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $1.600M $1.600M
YoY Change 23.08%
Total Short-Term Liabilities $6.027M $6.303M
YoY Change -10.04%
LONG-TERM LIABILITIES
Long-Term Debt $2.100M $2.500M
YoY Change -43.24%
Other Long-Term Liabilities $100.0K $200.0K
YoY Change -90.0%
Total Long-Term Liabilities $2.200M $2.700M
YoY Change -53.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.027M $6.303M
Total Long-Term Liabilities $2.200M $2.700M
Total Liabilities $8.200M $9.000M
YoY Change -28.07%
SHAREHOLDERS EQUITY
Retained Earnings -$72.94M -$64.82M
YoY Change
Common Stock $16.00K $16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.62M $46.23M
YoY Change
Total Liabilities & Shareholders Equity $46.82M $55.23M
YoY Change 438.21%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$8.121M -$7.222M -$5.512M
YoY Change 123.47% 31.02%
Depreciation, Depletion And Amortization $110.0K $100.0K $120.0K
YoY Change 0.0% -16.67%
Cash From Operating Activities -$8.450M -$5.030M -$5.420M
YoY Change 359.24% -7.2%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K $50.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$80.00K -$50.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $51.51M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -410.0K 51.11M 2.980M
YoY Change -111.82% 1615.1%
NET CHANGE
Cash From Operating Activities -8.450M -5.030M -5.420M
Cash From Investing Activities -80.00K -50.00K 0.000
Cash From Financing Activities -410.0K 51.11M 2.980M
Net Change In Cash -8.940M 46.03M -2.440M
YoY Change -648.47% -1986.48%
FREE CASH FLOW
Cash From Operating Activities -$8.450M -$5.030M -$5.420M
Capital Expenditures -$80.00K $50.00K $0.00
Free Cash Flow -$8.370M -$5.080M -$5.420M
YoY Change 354.89% -6.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
79000
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16261849 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5438000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16037232 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
402861 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16037232 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.17
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1414355 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.60
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1060715 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.21
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
457000
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111027000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3070000
CY2014Q1 us-gaap Notes Payable Current
NotesPayableCurrent
1642000
CY2014Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
240000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6303000
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
126000
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
46227000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64816000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1134000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55227000
CY2014Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
2466000
CY2014Q1 us-gaap Construction Payable Current
ConstructionPayableCurrent
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53964000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
443000
CY2014Q1 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
8000
CY2014Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
223000
CY2014Q1 us-gaap Interest Payable Current
InterestPayableCurrent
90000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Assets Current
AssetsCurrent
54407000
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2014Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
53964000
CY2014Q1 us-gaap Assets
Assets
55227000
CY2014Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53964000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
12300000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4500000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
708000
CY2014Q1 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000
CY2014Q1 ebio Deferred Offering Cost
DeferredOfferingCost
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7882000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1636137 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1636137 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.39
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1346238 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
77688009 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
850000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3260000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1746000
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1642000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5353000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
346000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
297000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54332000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57594000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1115000
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
297000
CY2013Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
62000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11237000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2876000
CY2013Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
10000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
355000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5420000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
759000
CY2013Q4 ebio Deferred Offering Cost
DeferredOfferingCost
180000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.14
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8271705 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1247000 shares
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
297000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
297000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
8030000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2354000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7942000
CY2013Q4 us-gaap Assets
Assets
11237000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
7942000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7942000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
88000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18000
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6405000
CY2013Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
31000
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2013Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-79000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5435000
CY2013Q1 us-gaap Interest Paid
InterestPaid
70000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-5512000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
939000
CY2013Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
9000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2976000
CY2013Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
28000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
39000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
115000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2444000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-51000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4496000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2013Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
893000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
5435000
CY2014Q1 dei Trading Symbol
TradingSymbol
EBIO
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7874 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.37
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M16D
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9635000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.85
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5034000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.06
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
80715 shares
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M11D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M28D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M13D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4724 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1618108 shares
CY2014Q1 us-gaap Revenues
Revenues
568000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
186000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7741000
CY2014Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
416000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-84000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7189000
CY2014Q1 us-gaap Interest Paid
InterestPaid
64000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7222000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1938000
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
8000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
51106000
CY2014Q1 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-113000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
120000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
636000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
101000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46022000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-50000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-215000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1885000
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
51507000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5819000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
CY2014Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
519000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
7757000
CY2014Q1 ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
56678000
CY2014Q1 ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
247000
CY2014Q1 ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
CY2014Q1 ebio Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
-50000
CY2014Q1 ebio Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Reclassification To Equity
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityReclassificationToEquity
247000

Files In Submission

Name View Source Status
0001193125-14-201170-index-headers.html Edgar Link pending
0001193125-14-201170-index.html Edgar Link pending
0001193125-14-201170.txt Edgar Link pending
0001193125-14-201170-xbrl.zip Edgar Link pending
d707097d10q.htm Edgar Link pending
d707097dex311.htm Edgar Link pending
d707097dex312.htm Edgar Link pending
d707097dex321.htm Edgar Link pending
ebio-20140331.xml Edgar Link completed
ebio-20140331.xsd Edgar Link pending
ebio-20140331_cal.xml Edgar Link unprocessable
ebio-20140331_def.xml Edgar Link unprocessable
ebio-20140331_lab.xml Edgar Link unprocessable
ebio-20140331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending